WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017060420) PROTECTED FUMARIC ACID-BASED METABOLITES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2017/060420    International Application No.:    PCT/EP2016/073989
Publication Date: 13.04.2017 International Filing Date: 07.10.2016
IPC:
C07D 309/30 (2006.01), C07C 327/06 (2006.01), C07C 327/34 (2006.01), C07C 327/36 (2006.01), C07D 211/76 (2006.01), C07C 327/08 (2006.01), A61K 31/225 (2006.01), A61P 9/00 (2006.01), A61P 35/00 (2006.01), A61P 37/00 (2006.01), A61P 17/06 (2006.01)
Applicants: NEUROVIVE PHARMACEUTICAL AB [SE/SE]; Medicon Village, Scheelevägen 2 223 81 Lund (SE)
Inventors: MOSS, Steven; (GB).
GREGORY, Matthew; (GB).
ELMÉR, Eskil; (SE).
HANSSON, Magnus Joakim; (SE)
Agent: CHAS. HUDE A/S; H.C. Andersens Boulevard 33 1780 København V (DK)
Priority Data:
PA 2015 70631 07.10.2015 DK
Title (EN) PROTECTED FUMARIC ACID-BASED METABOLITES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
(FR) MÉTABOLITES À BASE D'ACIDE FUMARIQUE PROTÉGÉ DESTINÉS AU TRAITEMENT DE MALADIES AUTO-IMMUNES
Abstract: front page image
(EN)The present invention provides novel cell-permeable fumarate acyl mercaptoethylamines (FAMs) which have cellular effects including induction of Nrf2 and inhibition of the NFkB pathway. These compounds have utility in medicine including their use in treatment of diseases such as Multiple sclerosis, Non-alcoholic Steatohepatitis, Psoriasis, Inflammatory Arthritis, Inflammatory Bowel Disease, Asthma, Chronic Obstructive Pulmonary Disease, Cancer, Parkinson's Disease, Alzheimer's Disease, Huntington's Disease and Amyotrophic Lateral Sclerosis.
(FR)La présente invention concerne de nouvelles mercaptoéthylamines de fumarate d'acyle (FAM) à perméabilité cellulaire qui possèdent des effets cellulaires comprenant l'induction de Nrf2 et à l'inhibition de la voie de NFkB. Ces composés sont utiles en médecine, notamment concernant leur utilisation dans le traitement de maladies telles que la sclérose en plaques, la stéatohépatite non alcoolique, le psoriasis, l'arthrite inflammatoire, la maladie inflammatoire chronique de l'intestin, l'asthme, la bronchopneumopathie chronique obstructive, le cancer, la maladie de Parkinson, la maladie d'Alzheimer, la maladie de Huntington et la sclérose latérale amyotrophique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)